Stellaromics is dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company’s mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health.
Standard BioTools
Standard BioTools™, previously known as Fluidigm, is driven by a bold vision Unleashing tools to accelerate breakthroughs in human health. Standard BioTools provides an established portfolio of essential, standardized next-generation technologies with CyTOF® and microfluidics capabilities to the cancer community. The company empowers biomedical researchers to interrogate immune cell function and the tumor microenvironment with unprecedented resolution for reliable and repeatable insights they can trust. Together we will transform the future of cancer care.
Spatomics
Based in Guilford, Connecticut, Spatomics is a spatial biology company focused on making high-plex tissue profiling practical, affordable, and reproducible. Our proprietary CFP™ cleavable tyramide technology enables iterative biomarker analysis on FFPE tissue samples while preserving tissue morphology and delivering clear, single cell level results, supporting 20+ plex detection. CFP™ reagents are compatible with standard primary antibodies and IHC/IF workflows, allowing labs to expand multiplexing without costly specialized reagents or major protocol changes. We have also developed a compact, low-cost staining instrument that streamlines key steps in the process, improving efficiency and lowering the barrier to adoption. Together, our chemistry and instrumentation platform makes advanced spatial profiling more accessible to research laboratories.
Signal Bioscience
Signal Bioscience is a life science tools company developing novel Processor-Mediated PCR (pmPCR) chemistries that dramatically expand the multiplexing, sensitivity, and speed of existing qPCR and dPCR instruments. Our platform enables up to 25-plex in qPCR and 100-plex in digital PCR — without new hardware — by precisely controlling signal intensity and timing within a single fluorescence channel. We are developing high-impact applications in oncology, including multiplex KRAS mutation detection, HPV-associated cancer monitoring, and minimal residual disease (MRD) liquid biopsy assays.
SeqMatic
SeqMatic is an experienced OMICS SERVICES LABORATORY offering full and partial NGS workflow services for DNA, RNA, Single Cell, Epigenetics, Spatial, Proteomics, Histology, and Bioinformatics (primary, secondary, tertiary). Our specialized assays include micro and small RNA workflows to detect cancer triggers, & multi-omics approaches to better characterize the tumor microenvironment. We are introducing a new sample enrichment service designed specifically for FFPE solid tumor samples with low tumor content. This unique workflow combines high-precision masking with AI-driven digital pathology to enable automated enrichment of anatomically defined regions of interest (ROIs). Visit our booth to see data demonstrating our ability to accurately locate, isolate, separate, and consolidate pure tumor tissue from FFPE blocks or slides—and to generate high-quality NGS data from samples that would otherwise fail. Looking for a CLIA/CAP lab partner to validate and run your custom NGS assay as an LDT? SeqMatic offers full or partial wet-lab onboarding and validation, dry-lab support as needed, and process optimization to improve assay performance while reducing turnaround time and cost. We support batch sizes ranging from a handful of samples to thousands per week. All work is performed in our CLIA/CAP-certified laboratory in Fremont, CA, and we are 100% BIOSECURE Act compliant.
SeqOne
SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under HIPAA as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. | SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.
SensID, a Microbiologics Company
“Microbiologics helps cancer researchers and diagnostic developers trust every result with high-quality reference materials from our SensID portfolio. SensID products are designed to reflect real clinical samples and support assay development, validation, and ongoing quality control across molecular oncology testing. Our portfolio spans key material types, including: human genomic DNA (gDNA) controls, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) for liquid biopsy assays, human-tech plasma for full workflow controls, and formalin-fixed paraffin-embedded (FFPE) standards for solid tumor applications. Well-known examples include EGFR-Multiplex cfDNA sets for mutation detection across allele frequencies, ESR1 & PIK3CA reference sets for precision liquid biopsy quality control, and MSI/MSS FFPE reference materials to mimic patient samples in microsatellite instability testing. Researchers use SensID products to validate NGS and PCR assays, benchmark instrument performance, and monitor routine operations with confidence. Backed by deep genomic characterization and consistent lot performance, SensID materials help you advance oncology workflows with clarity and reliability.”
Scientist.com
Scientist.com is the world’s largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies. Scientist.com operates private marketplaces for most of the world’s major pharmaceutical companies and the US NIH. Visit scientist.com to learn more.
SBDX
Human tissue biobank. We supply high quality FFPE tissues for research, controls, IHC validation and pharma development. Our inventory consists of malignant tumors of all types, normal tissue, diseased tissue and tissues with known IHC results, genetic mutations and other specific criteria to support your projects.
Sapient
Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development. Utilizing cutting-edge, high throughput mass spectrometry, we make nontargeted and targeted measurements to capture thousands of dynamic biomarkers – including proteins, metabolites, and lipids – per sample, across thousands of samples at a time. We pair this with advanced biocomputational frameworks enabling comprehensive biomarker-phenotype mapping for discovery of robust biomarkers, drug targets, and clinical signatures of drug response. Aided by our DynamiQ™ Insights Engine — a longitudinal database of integrated multi-omics and real-world data collected in tens of thousands of samples — we can support rapid drug target identification, biomarker discovery and validation, and translational insights across all stages of drug development, including clinical trials.